May 21, 2024
“Sutro Biopharma (STRO)… “We think that luvelta has the potential to treat up to 80% of PROC patients, a significant improvement over the ~30% eligible for AbbVie’s Elahere (approved FolRα ADC)… Overall, the Strong Buy consensus rating on STRO is based… Continue Reading…
Recent Comments